Latest 10-Q quarterly reports

Priority Technology Holdings, Inc. (PRTH) filed its Form 10-Q for the quarterly period ended June 30, 2026, detailing revenue growth driven by its Merchant Solutions and Treasury Solutions segments, alongside significant strategic acquisitions.

Praxis Precision Medicines, Inc. (PRAX) filed its Q2 2026 10-Q, detailing strong cash position, progress on multiple drug candidates, and a setback in the vormatrigine program.

Valaris Limited's Q2 2026 Form 10-Q reveals a sequential revenue increase and stable operational metrics, with continued progress on its pending merger with Transocean Ltd.

Aemetis, Inc. reported increased revenues for Q2 2026 driven by its California Ethanol and RNG segments, but faces significant debt obligations and a going concern warning.

MarketWise, Inc. reported a net loss of $2.6 million for the second quarter of 2026, with net revenue decreasing by 5.2% year-over-year, despite a significant 56.7% increase in total billings.

Oyster Enterprises II Acquisition Corp reports continued operation as a SPAC, generating interest income from its trust account while actively seeking a business combination before its May 2027 deadline.

Sonoma Pharmaceuticals, Inc. announced a 60% year-over-year revenue increase for the first quarter ended June 30, 2026, driven by strong international sales and improved gross profit margins.

Acorn Energy reported a 29% year-over-year revenue decline for the second quarter of 2026, with net income attributable to stockholders falling by 82%.

CRA International's Q2 2026 results show a 12.8% revenue increase driven by higher utilization and a shift to fixed-price contracts, though net income saw a year-to-date decline due to increased operational expenses.

Aurinia Pharmaceuticals Inc. announced significant revenue growth for LUPKYNIS and a substantial increase in operating cash flow for the second quarter of 2026.

Patrick Industries announced its second quarter 2026 financial results, showing a 34% increase in net income year-over-year, alongside a significant pending merger with LCI Industries.

Globalstar, Inc. reported a net loss for the quarter ended June 30, 2026, with total revenue seeing a slight decrease, though certain service segments showed growth, all while navigating the pending acquisition by Amazon.

Aligos Therapeutics reported a net loss for the quarter and six months ended June 30, 2026, with cash reserves projected to last only into Q4 2026, raising substantial doubt about its going concern status.

MBX Biosciences reports a widening net loss in Q2 2026 driven by increased research and development expenses, though the company maintains a substantial cash reserve and advances its pipeline.

Edgewise Therapeutics details progress in cardiovascular pipeline and completion of sevasemten program sale, reporting a net loss of $57.3 million for Q2 2026.

Ecolab Inc. announced a 10% increase in reported net sales and a 7% rise in operating income for the second quarter of 2026 compared to the prior year.

Prime Medicine, Inc. filed its Q2 2026 10-Q, detailing continued operating losses and a significant accumulated deficit, while also highlighting progress in its gene editing therapies and receiving RMAT designation.

Hertz Global Holdings, Inc. reported a 10% increase in total revenues for the first half of 2026, driven by improved pricing, though operating costs and depreciation also rose.

Rallybio Corporation filed its Form 10-Q for the quarter ended June 30, 2026, detailing financial results, ongoing merger plans with Avenzo Therapeutics, and operational updates.

Twin Vee PowerCats Co. reported a significant decrease in net sales and an increase in net loss for the second quarter of 2026, while facing substantial doubt about its ability to continue as a going concern.

AquaBounty Technologies reports continued net losses and substantial doubt about its ability to continue as a going concern, despite recent capital raises and strategic asset sales.

BlackRock TCP Capital Corp. filed its quarterly report, detailing a decrease in net asset value per share and a significant negative total return, while also addressing ongoing legal proceedings and a recent CLO transaction.

Sabre Corporation reported a 4% increase in revenue for the second quarter of 2026, reaching $712 million, but continued to post net losses.

Lantheus Holdings reports Q2 2026 revenue growth driven by key products, while navigating a pending acquisition and regulatory updates.

Burford Capital Limited announced a substantial net loss for the six months ended June 30, 2026, primarily due to a significant write-down related to the YPF Judgment Reversal.

Compass Therapeutics reports increased R&D and G&A expenses in Q2 2026, alongside promising but mixed clinical trial results for its lead candidate, tovecimig.

Acadian Asset Management Inc. announced a substantial increase in revenue and assets under management for the second quarter of 2026, driven by strong market performance and positive client flows.

SAB Biotherapeutics, Inc. reported a net loss of $22.5 million for the second quarter of 2026, with operating expenses nearly tripling year-over-year, driven by increased clinical trial costs for its lead candidate SAB-142.

Paysign, Inc. announced a substantial increase in revenues and net income for the second quarter of 2026, driven by strong performance in its plasma and pharma industry segments.

Tanger Inc. announces a significant increase in net income and revenues for Q2 2026, driven by higher rental income and strategic property acquisitions.